Bone Marrow Transplantation in Nonmalignant Haematological Diseases: What Have We Learned about Thalassemia?
Open Access
- 24 April 2023
- journal article
- review article
- Published by MDPI AG in Thalassemia Reports
- Vol. 13 (2) , 122-130
Abstract
Allogeneic stem cell transplantation remains the only therapy for congenital, severe haemoglobinopathies that is able to reverse the pathological phenotype. In the severe form of thalassemia, regular transfusions are needed early in life. This population of patients could benefit from allo-SCT. However, the great efficacy of transplantation must be counterbalanced by the mortality and morbidity related to the procedure. In this short review, we reviewed the most recent data in the field of transplantation in transfusion-dependent thalassemia (TDT), highlighting the factors that have a major impact on outcomes.Keywords
This publication has 35 references indexed in Scilit:
- Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell GraftsPLOS ONE, 2013
- HLA-matched sibling bone marrow transplantation for β-thalassemia majorBlood, 2011
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Complete substitution of cyclophosphamide by fludarabine and ATG in a busulfan-based preparative regimen for children and adolescents with β-thalassemiaBone Marrow Transplantation, 2005
- New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 yearsBlood, 2004
- Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantationBone Marrow Transplantation, 2000
- The role of thiotepa in allogeneic bone marrow transplantation for genetic diseasesBone Marrow Transplantation, 1999
- Marrow Transplantation in Patients with Advanced ThalassemiaNew England Journal of Medicine, 1987
- MARROW TRANSPLANTATION FOR THALASSAEMIA FOLLOWING BUSULPHAN AND CYCLOPHOSPHAMIDEThe Lancet, 1985
- Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and CyclophosphamideNew England Journal of Medicine, 1983